Fireman B.V. (IFRX) Stock Price, Quote & News

Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa,...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 3641 508 180

Website: www.inflarx.de

Address:

Winzerlaer Str. 2, Jena, Germany

StartSlow Aug. 27 at 1:56 PM

$IFRX day by day small steps up, this is how it should be 👍

0 · Reply

GMSinvest Aug. 27 at 1:34 PM

$IFRX where’s that PR on PG topline results? 🧐

0 · Reply

MrCompassion Aug. 27 at 9:31 AM

$IFRX Had me a chat, GPT style. START It ended with this GPT response: “This isn’t just another case report — if a ‘worst-ever PG case’ healed with vilobelimab and it’s told through a compelling patient narrative, the story would resonate from local TV news → national newspapers → biotech finance press. It would likely be framed as ‘novel therapy saves life when all else failed’, sparking hope among patients, attention from doctors, and momentum for the company with investors and regulators.” P1: On Sept 17, Dr. Alavi, who treats PG patients at the Mayo Clinic in Minnesota, will be providing info on the following: “Vilobelimab induced C5a suppression correlates with clinical benefit and pain reduction in patients with ulcerative pyoderma gangrenosum.” There are two ways to look at this: 1. Vilo is able to safely, efficiently, substantially, and sustainably suppress C5a, and 2. Controlling C5a-C5aR1 signaling enables the noted quality of life improvements of these

5 · Reply

Barkingdogs Aug. 27 at 8:21 AM

$IFRX only people are stupid..markets figure out truth 🤑🤮😀🤑🤮😀

0 · Reply

levystrauss Aug. 26 at 3:24 PM

$IFRX Niels and Inflarx have accustomed us to constant failures and dilution. Only by changing this sad state of affairs and seeking outside help can we save ourselves and perhaps see better times. We must be realistic and not defend Niels for his obvious mistakes, both in finance and in finding serious and reliable partners. Having a product approved in the US and Europe and not selling anything is a real disgrace. It would be better to fire the sales team and take Gohibic off the market, saving many millions of dollars. But he continues on his wrong path.

0 · Reply

levystrauss Aug. 26 at 3:16 PM

$IFRX If, as usual, Niels' pipeline fails and the November figures are negative, we risk Chapter 11 bankruptcy. Let's hope not, otherwise we'll lose all our money, and what will happen to Mr. Compassion?

0 · Reply

levystrauss Aug. 26 at 3:15 PM

$IFRX The royalties that Staidson will give to Inflarx are approximately 5% if the product is approved and sold in China. So if Staidson sells perhaps $100 million of the drug in 2030, Inflarx will only get $5-6 million. The market isn't stupid; Inflarx has been under $1 for many months due to the failure of its Phase 3 pipeline. One failure after another for Niels. Let's hope the new Phase 2 pipeline, whose data were delayed until November, doesn't fail as well. Let's hope Niels doesn't dilute the market again, as usual.

1 · Reply

TheGhostOfEd Aug. 26 at 2:56 PM

$IFRX inf904 CT page updated on 8/20 with a bunch of new locations

1 · Reply

TheGhostOfEd Aug. 26 at 2:56 PM

$IFRX to the rimbambito below, Staidson needs to actually have one of their vilo licensed drugs as an approved drug with sales in order to collect royalties...that's way down the line.

0 · Reply

levystrauss Aug. 26 at 2:48 PM

$IFRX Our Chinese partner has risen, but we have no benefit. The market, you don't have to convince me, but the market is not stupid.

0 · Reply

InflaRx Announces Participation in September Investor Conferences

Aug 7, 2025, 7:30 AM EDT - 20 days ago

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:30 AM EDT - 27 days ago

InflaRx to Report Second Quarter 2025 Results on August 7, 2025

Jul 11, 2025, 4:15 PM EDT - 6 weeks ago

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

May 28, 2025, 11:00 AM EDT - 3 months ago

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

May 28, 2025, 1:30 AM EDT - 3 months ago

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

May 22, 2025, 7:30 AM EDT - 3 months ago

InflaRx to Participate in Upcoming Investor Conferences

May 7, 2025, 7:30 AM EDT - 4 months ago

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 4 months ago

InflaRx to Report First Quarter 2025 Results on May 7, 2025

Mar 20, 2025, 7:30 AM EDT - 5 months ago

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Mar 7, 2025, 8:00 AM EST - 6 months ago

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 28, 2025, 9:00 AM EST - 6 months ago

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Feb 25, 2025, 7:30 AM EST - 6 months ago

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Feb 18, 2025, 4:01 PM EST - 6 months ago

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 9:45 PM EST - 6 months ago

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2025, 4:01 PM EST - 6 months ago

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

Jan 23, 2025, 7:30 AM EST - 7 months ago

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Jan 15, 2025, 12:30 PM EST - 7 months ago

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

Dec 20, 2024, 7:30 AM EST - 8 months ago

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

Nov 15, 2024, 7:51 AM EST - 10 months ago

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

Nov 8, 2024, 7:30 AM EST - 10 months ago

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 25, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

Sep 3, 2024, 7:30 AM EDT - 1 year ago

InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases

Aug 27, 2024, 7:30 AM EDT - 1 year ago

InflaRx Announces Participation in September Investor Events

Aug 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Report Second Quarter 2024 Results on August 8, 2024

Jun 24, 2024, 8:02 AM EDT - 1 year ago

InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)

Jun 5, 2024, 12:00 PM EDT - 1 year ago

InflaRx Hosts R&D Event Highlighting the Promise of INF904

May 21, 2024, 2:30 PM EDT - 1 year ago

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

May 8, 2024, 7:30 AM EDT - 1 year ago

InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event

Mar 21, 2024, 7:00 AM EDT - 1 year ago

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

Mar 19, 2024, 7:30 AM EDT - 1 year ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Feb 22, 2024, 7:30 AM EST - 1 year ago

InflaRx Appoints Jan Medina as Head of Investor Relations

Jan 25, 2024, 7:30 AM EST - 1 year ago

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

Jan 4, 2024, 7:00 AM EST - 1 year ago

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Nov 6, 2023, 7:30 AM EST - 1 year ago

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Nov 1, 2023, 7:30 AM EDT - 1 year ago

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Sep 11, 2023, 7:00 AM EDT - 2 years ago

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Sep 6, 2023, 5:31 PM EDT - 2 years ago

InflaRx: Small German Company Targeting A Rare Indication

Aug 30, 2023, 7:30 AM EDT - 2 years ago

InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Aug 10, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

Jun 28, 2023, 7:30 AM EDT - 2 years ago

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Jun 21, 2023, 7:00 AM EDT - 2 years ago

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

May 16, 2023, 4:00 AM EDT - 2 years ago

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

May 11, 2023, 7:30 AM EDT - 2 years ago

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

Apr 18, 2023, 4:01 PM EDT - 2 years ago

InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million

Apr 14, 2023, 4:01 PM EDT - 2 years ago

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

Apr 11, 2023, 9:08 PM EDT - 2 years ago

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

Apr 11, 2023, 4:00 PM EDT - 2 years ago

InflaRx Announces Public Offering of Ordinary Shares

StartSlow Aug. 27 at 1:56 PM

$IFRX day by day small steps up, this is how it should be 👍

0 · Reply

GMSinvest Aug. 27 at 1:34 PM

$IFRX where’s that PR on PG topline results? 🧐

0 · Reply

MrCompassion Aug. 27 at 9:31 AM

5 · Reply

Barkingdogs Aug. 27 at 8:21 AM

$IFRX only people are stupid..markets figure out truth 🤑🤮😀🤑🤮😀

0 · Reply

levystrauss Aug. 26 at 3:24 PM

0 · Reply

levystrauss Aug. 26 at 3:16 PM

0 · Reply

levystrauss Aug. 26 at 3:15 PM

1 · Reply

TheGhostOfEd Aug. 26 at 2:56 PM

$IFRX inf904 CT page updated on 8/20 with a bunch of new locations

1 · Reply

TheGhostOfEd Aug. 26 at 2:56 PM

$IFRX to the rimbambito below, Staidson needs to actually have one of their vilo licensed drugs as an approved drug with sales in order to collect royalties...that's way down the line.

0 · Reply

levystrauss Aug. 26 at 2:48 PM

$IFRX Our Chinese partner has risen, but we have no benefit. The market, you don't have to convince me, but the market is not stupid.

0 · Reply

Barkingdogs Aug. 26 at 2:25 PM

$IFRX here's our China partner ..Levy can you see 🤑🤑🤑

0 · Reply

Barkingdogs Aug. 26 at 1:57 PM

$IFRX volume always preceeds price....are you watching. Get in or get out of the way

1 · Reply

dogDazeSummer Aug. 26 at 11:40 AM

There were 3 instances at end of Q2 whereby RA Capital added shares to existing positions (only 63 positions in total w $6B AUM) — and similar biotech funds also added. $CDTX biggest add to existing.$10.14 - $69.46 52 wk There were 6 brand new starter positions for RA Capital, 4 of which were “IPO”: HNGE- IPO May 2025 JBIO- reverse merger OMDA - IPO June 2025 WGS- turnaround story However 2 of the new adds have similarities (not IPO, reverse merger / SPAC), both have pending readout 2H2025 for multi $B opptys. $IFRX- $.71- $2.71 -52 wk INF904 Phase 2a for CSU and HS RA Capital had 0 shares at Q125, but added alongside Ikarian and Adage —all 3 taking starter positions. RA: 0 to 1,973,233 Adage: 0 to 331,133 Ikarian: 0 to 705,010 $TNGX $1.03- $11.97-52wk TNG462 and TNG456 Phase 1/2 RA Capital had 0 shares at Q125, but added alongside Adage —many others taking starter positions: RA: 0 to 2,000,000 Adage: 0 to 5,905,394 Woodline: 506,731 to 6,029,906

2 · Reply

dogDazeSummer Aug. 26 at 1:07 AM

RA Capital has owned 628,092 shares of $ASMB *since February 2013* but suddenly increased their ownership to 1,530,615 (up to 9.5%) as of 8/18/25? 10 years later? Why did they own $IFRX in 2019, drop to 0 holdings - yet back up to 1,972,933 as of 6/30/25? Follow the leader.

2 · Reply

MrCompassion Aug. 25 at 11:10 PM

$IFRX Chapter 7 Ryan and his wife are planning a proper walk-down-the-aisle wedding Sept 3, 2025. Congratulations! Quite the real-world experience for the most famous PG case perhaps of all time. It was about 6 months back, early April that Ryan was started on Tremfya (100 mg in a pre-filled syringe to be injected subcutaneously every 4 weeks for 28 weeks) as per its PG p2 study protocol. Back in chapter 5 (April 22 post), I had mentioned about an update video that Ryan posted on facebook indicating “a second drug as part of treatment, to be administered every 2 weeks, one which requires travel to Oregon.” That video was promptly taken down a day or so later. Can’t image why. By my estimate, Ryan would have been started on this mystery biweekly drug May 2. That equates to 9 injections as of Aug 22. Today Ryan’s wife provided this update: “Ryan is still here today thanks to an experimental trial of a novel biological therapeutic, but every day is a fight. He continues to

2 · Reply

cielo1 Aug. 25 at 10:19 PM

$IFRX walked down like true professional short attack and or pInning for low ball BO. Mgmt needs an intervention to level up...! All the best to all!!

1 · Reply

Barkingdogs Aug. 25 at 5:52 PM

$IFRX Levy it's time to leave. If you all miss this you will think about it for years!! Stupid Nils was the one who said it could revolutionize medicr. Guess what Staidson said the same and went from 6 to 60. Aren't you in the market to win!! Get in or get love st....

1 · Reply

levystrauss Aug. 25 at 3:38 PM

$IFRX Remember, Niels isn't doing what's best for his shareholders, as he's demonstrated over the past six years. He doesn't want to make deals because he proudly believes he's right and wants all the glory for himself. The Bible says that pride comes before a crash. He's going down this path. Let's hope he changes his mind and that the figures are good.

0 · Reply

levystrauss Aug. 25 at 3:36 PM

$IFRX To date, Inflarx and its CEO have failed on many pipelines, and the stock has plummeted from $20 to $0.90 over several years (about six years). The CEO shouldn't be trusted; he could give retail investors another push by delaying the data (hopefully good, but no one knows) that was supposed to be released this summer, resulting in significant dilution.

1 · Reply

levystrauss Aug. 25 at 3:33 PM

$IFRX Standard Royalties (Original Co-Development Agreement) for Other Uses Since 2015, InflaRx had already granted BDB (then Staidson, which assumed the rights in 2021) an exclusive license to use the vilobelimab cell line in China to develop and commercialize BDB-001 and BDB-002. Under this original agreement, InflaRx is entitled to mid-single-digit royalties on net revenues from products containing BDB-001 or BDB-002. SEC quarterlytics.com Recent Developments (2025) In Q2 2025, InflaRx announced that, under the co-development agreement in China, it will receive mid-single-digit royalties on future sales of BDB-001 used for indications such as ANCA-associated vasculitis (AAV).

0 · Reply

levystrauss Aug. 25 at 3:29 PM

$IFRX The Staidson deal isn't very important for Inflarx. In fact, it didn't benefit from the huge rise in Staidson stock. The market isn't stupid.

0 · Reply

dogDazeSummer Aug. 25 at 3:23 PM

$IFRX What do these 3 entities have in common? Capstan Therapeutics: autoimmune diseases. LMP $2.1 billion in cash, Phase 1, August 2025, this month Immunogen: Antibody-drug conjugates (ADCs) for cancer. $10.1b ,February 2024, Phase 2 Aliada Therapeutics: Central nervous system (CNS) drug delivery for neurological diseases. Alzhiemers-- $1.4 billion in cash, Phase 2 December 2024 All were Peter KOL-Chinsky portfolio companies at RA Capital during last year Initial investment by RA Capital was under $100M valuation. All were sold to “a good friend”, $ABBV over $1B- Thank you Peter All are pipeline type entities None had FDA approved drug This is not an exhaustive list of RA entities sold to Abbie. It’s just recent entry <$100M exit > $1B Wonder if RA needs to reload its pipeline? Its amazing what can occur with timing, collaboration and the right relationships.

2 · Reply

Market Cap	61.33M
Revenue (ttm)	180,000.00
Net Income (ttm)	-49.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-27,694.44%
Debt to Equity Ratio	0.00

Volume	428,100
Avg Vol	294,802
Day's Range	N/A - N/A
Shares Out	67.13M
Stochastic %K	78%
Beta	1.29
Analysts	Strong Sell
Price Target	$4.00